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CURRENT OPINIONClinical relevance of a p value: Does tranexamic acid save
lives after trauma or postpartum hemorrhage?Geoffrey P. Dobson, PhD, FAHA, Kenji Doma, PhD, and Hayley L. Letson, PhD,
Townsville, Queensland, Australia“T ranexamic acid could save the lives of one in threemothers who would otherwise bleed to death
after childbirth.” —Chief Investigators WOMAN1
Hemorrhage Control After Traumatic and
Obstetric Injury
Tranexamic acid (TXA), an antifibrinolytic agent, has
been widely publicized as saving lives after traumatic hemor-
rhage in the CRASH-2, MATTERs, and PED-TRAX trials2–5
and more recently after postpartum hemorrhage (PPH) in the
World Maternal Antifibrinolytic (WOMAN) trial.6 Prophylactic
administration of TXA is also increasingly used in major elec-
tive and emergency surgery to reduce excessive bleeding, trans-
fusion requirements, and possible reexploration.7
Despite the claims of mortality reduction, ongoing contro-
versies exist around the CRASH-2 trial data8–11 and more re-
cently with the WOMAN trial data.6 Mortality reduction has
been showcased on theWOMAN trial's chief investigator's insti-
tutional Web site1 and perpetuated by social media. This new
strategy of communication and engagement appears to be driv-
ing a global movement among trauma surgeons and clinicians
to persuade their medical advisory boards, or equivalent, to sug-
gest that there are enough data towarrant administration of TXA
in the field or clinic. It also appears to influence global health
care providers and stakeholders regarding clinical, public health,
or policy recommendations on TXA use.
In this current opinion, we return to the original data of
both trials and address the notion that small p values and large
sample sizes (>20,000 patients each) are sufficient to support
clinical use of a drug, such as TXA. We encourage health care
professionals, scientists, and governing bodies to compare the
actual data with precision of the results by comparing confi-
dence intervals (CIs). Different conclusions can be formulated
from an overreliance of statistical significance ( p values) without
paying due attention to the magnitude of group differences.12 We
will first discuss the WOMAN trial followed by the CRASH-2
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Tranexamic acid is a synthetic lysine analog that can reduce
active bleeding by blocking the lysine-binding sites on fibrinogen
and fibrin resulting in inhibition of tissue plasminogen activator
(tPA)–mediated fibrinolysis13 (Fig. 1). In some physiological
states, TXA may paradoxically increase bleeding by binding to
plasminogen in the presence of increased levels of urokinase
plasminogen activator (uPA) and facilitate plasmin formation,
which is independent of tPA10,14 (Fig. 1). The plasma half-life
of TXA is approximately 2 hours, and its antifibrinolytic effects
may last up to 7 to 8 hours in blood and approximately 17 hours
in different tissues.13,15 Increased interest in TXA use in trauma
settings and major surgery occurred 10 years ago after a newer,
more potent antifibrinolytic, aprotonin, was removed from
world markets.16,17 With respect to TXA's potential to reduce
blood loss and mortality, it is important to note that lysine is
an essential amino acid involved in multiple functions such as
protein building, metabolic signaling events (via acetylation),
protein-protein interactions, and posttranslational modifications
in immunity and inflammation.18 It is not known how TXA af-
fects these homeostatic functions.The WOMAN Trial Design and Main Findings
The WOMAN trial has been heralded across social media
as a breakthrough in PPH treatment driven in part by the chief
investigator's institutional Web site.19 The WOMAN trial was a
randomized, double-blind, placebo-controlled trial investigating
the use of TXA.6 Mothers were recruited from 193 hospitals and
21 countries, mainly in Africa and Asia, but also in the United
Kingdom, and the trial was funded by The Wellcome Trust
and UK Department of Health through the Health Innovation
Challenge Fund, as well as the Bill & Melinda Gates Foundation.
The trial was originally planned to enroll 15,000 women
with a composite primary end point of death from all causes or
hysterectomy within 42 days of giving birth.6 The patient num-
bers were increased to more than 20,000 “in the hope that the
trial would have enough power to detect a reduction in post-
partum hemorrhage death,” and the primary end point was re-
vised to be a measure of “death from post-partum hemorrhage.”6
The study reported that TXA significantly reduced the risk
of death from bleeding from 1.9% (191 deaths) to 1.5% (155
deaths) ( p = 0.045).6 Further reductions in mortality were found
if TXA was given within 3 hours of giving birth (1.7–1.2%
[ p = 0.008]) or a decrease from 127 to 89 women given treat-
ment versus placebo (in addition to standard care).6 There wereJ Trauma Acute Care Surg
Volume 84, Number 3
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Figure 1. Tranexamic acid is a synthetic derivative of the amino acid lysine that inhibits tPA-mediated fibrinolysis by blocking the
five lysine-binding sites on circulating plasminogen. Circulating plasminogen is converted to the serine protease plasmin by the enzyme
tPA, causing the breakdown of fibrin to D-dimers and other fibrin degradation products. Thus, TXA prevents plasmin from forming
and prevents the breakdown of fibrin clots. In some cases, such as in the brain, TXA can increase bleeding by binding to plasminogen in
the presence of increased levels of uPA levels, which can facilitate plasmin formation independent of tPA effect (see text).
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TXAwas given more than 3 hours after giving birth (p = 0.70)
(Fig. 2) or from all causes (p = 0.16). The WOMAN Trial Col-
laborators concluded, “When used as a treatment for post-
partum hemorrhage, TXA should be given as soon as possible
after bleeding onset.”6 We strongly believe that this statement
and the generalization that “tranexamic acid could save the lives
of one in three mothers whowould otherwise bleed to death after
childbirth”1 are a gross distortion of the data and may be mislead-
ing to health professionals and the public.
Relationship Between p Value, CI, and Sample Size
Fisher used the p-value as an index of evidence against
the null hypothesis with this straightforward logic: when the
p-value obtained from an experiment is small, then one
has to assume that either an unusual event has occurred or that
there is something wrong with the conditioning of the probability.
Faulty conditioning would mean that the null hypothesis
is not true.—Quoted from Lew20 (2012)
In theWOMAN trial, how does one interpret p = 0.008 for
mortality reduction when TXAwas administered for PPHwithin
3 hours after childbirth when the cutoff value to reject the null
hypothesis was 0.05? A p value of 0.008 means there are eight
in a thousand chances of being wrong, which sounds compel-
ling, but there are limits to how far we can extrapolate the statis-
tical data to TXA's lifesaving potential. In the WOMAN trial,
p = 0.008 denotes a 0.8% probability of observing a mortality© 2017 Wolters Kluwer Health, Inc. All rights reserved.
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esis (that there is no effect) and would indicate the null hypoth-
esis be rejected. However, the question of the “magnitude of
difference between TXA and placebo groups” requires knowl-
edge of the CI.21,22 The CI can be simply defined as the proba-
bility that a value will fall within the upper and lower bounds of
a set probability distribution, and therefore it represents a range
of values where an investigator is reasonably sure (95% confi-
dent) that the “true value” will be found. In the WOMAN trial,
the CI for p = 0.008 was 0.52 to 0.91, which is wide, and al-
though it indicates a direction of effect, it lessens the strength
of the data because the upper bound approaches 1.0 (Fig. 2).
A wide CI also implies the sample size is too small,21,22 and
given that the sample size was increased by 33% from 15,000
to 20,000, presumably to reach significance, the data remain
highly variable. To reduce variability (reduce the CI band-
width) in half, you would have to quadruple the sample size to
80,000 patients.22
In addition, analysis of the entire patient population who
died of bleeding in theWOMAN trial also showed statistical sig-
nificance between TXA and placebo groups within the 95% CI
( p = 0.045). However, on closer inspection, the CI of the relative
risk (RR) includes the null value of 1 (0.65–1.00), which further
reduces one's confidence for a clinical effect to reduce mortality
in the entire population. Therefore, the significant differences in
the WOMAN trial appear to be marginal at best and do not sup-
port the generalization on the chief investigator's Web site,
which went viral on social media, that “tranexamic acid could533
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Figure 2. Schematic of the effect of TXA on mortality risk and their associated CIs in three separate studies: the WOMAN trial,
CRASH-2 trial, and a military study (see text). Statistical significance in each trial was assessed using 95% CIs. In analyzing the data,
the “no effect” occurs when the CI touches 1.0 for RRs, or if the upper-bound CI or RR is closer to 1.0; this indicates reduced clinical
relevance despite a significant difference (low p value). In our schematic, RR or HR values of less than 1.0 indicate increased
survival, whereas greater than 1.0 indicates no change or increased risk of death. HR indicates hazard ratio; NS, not significant;
RR, risk ratio; S, significant. RR provides the cumulative risk over a time interval, whereas HR gives the instantaneous risk at a
particular time point. n/N denote the original sample size/final sample size.
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to death after childbirth.”
Statistical Versus Clinical Significance
Another important question that arises from theWOMAN
trial is whether a 0.4% to 0.5% difference in mortality reduction534
Copyright © 2018 Wolters Kluwer Hfrom bleeding is clinically relevant. The problem, as alluded to
above, is that any small difference will be statistically significant
if the sample size is large enough, regardless of clinical rele-
vance. As stated by Houle and Stump:23 “Many large clinical tri-
als obtain a high level of statistical significance with miniscule
differences between groups, which are completely clinically© 2017 Wolters Kluwer Health, Inc. All rights reserved.
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made from results of dubious clinical importance.”
Judgments about clinical importance should be based on
the magnitude of the effect and CIs rather than a p-value alone,
as the latter is strongly influenced by the size of the study.21,22 If
the WOMAN trial kept its original sample size of 15,000, would
the results be different? As it stands, in our opinion, there ap-
pears insufficient evidence to recommend TXA's widespread
use in PPH in the World Health Organization's List of Essential
Medicines or treatment guidelines based solely on theWOMAN
trial data alone. We offer an alternate interpretation of the
WOMAN trial data:
We are 95% confident that TXA may not save the lives
of one in three women who would otherwise bleed to death after
childbirth. Despite showing statistically significant p values in
mortality reduction, the close proximity of the RR to 1.0 and
upper limit of CI being close to or exceeding 1.0 imply
imprecision of the data and diminish its clinical relevance for
widespread TXA use in PPH.
It Is Only the Beginning: A Case for the Development
of New Diagnostics and Precision-Based Medicine
Unfortunately, theWOMAN trial did not address key clin-
ical questions on optimal dose or whether all women should re-
ceive TXA. What was the justification for administering TXA
to patients with an estimated blood loss less than 500 mL,
which falls below the normal PPH diagnostic guidelines? Of
the 52% of women who lost 1 L or blood or less, how many
died? This information was not forthcoming. Further, why was
there no subgroup analysis of mortality risk based on severity
of PPH? What laboratory tests are recommended to define a
TXA-treatable coagulopathy with hyperfibrinolysis? What were
the levels of uPA in blood of hemorrhaging women? Did any
patients have fibrinolytic shutdown? Should diagnostics include
plasmatic coagulation prothrombin time, activated partial throm-
boplastin time tests, whole-blood viscoelastic methods (throm-
boelastography, rotational thromboelastometry), fibrinogen levels,
tPA, or tPA/plasminogen activator inhibitor 1 ratios? What clin-
ical criteria drive TXA's use? What is the scientific basis for
these clinical decisions?
Similar questions have persisted with the 2010 CRASH-2
trial, a large multicenter, randomized, and placebo-controlled
trial in traumatic hemorrhage. The trial showed that TXA (1-g
loading dose over 10minutes followed by an infusion of 1 g over
8 hours) reduced bleeding and decreased 28-day mortality
(Fig. 2).5,8 However, the trial did not show a reduction in blood
transfusions,5,24 and there are ongoing controversies over TXA's
safety and efficacy to reduce mortality in specific trauma popu-
lations.5,10 If administered 3 hours after hemorrhage, TXA actu-
ally increased the risk of mortality (Fig. 2).2,10 In contrast, if
administered within 3 hours of injury, TXA appeared to have a
survival benefit (Fig. 2).
The early survival benefit of TXA in the CRASH-2 trial
was further supported by the MATTERs study, a Retrospective
Observational Registry study where TXAwas used with blood
component-based resuscitation in combat-related trauma.3 How-
ever, a more recent and larger military Retrospective Observa-
tional Registry study did not support the conclusions of the© 2017 Wolters Kluwer Health, Inc. All rights reserved.
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difference in mortality using TXA11 (Fig. 2). Despite the con-
flicting results on mortality reduction, there are many outstand-
ing questions regarding the potential detrimental effects of TXA
such as pulmonary embolism11 and exacerbation of secondary
injury processes, including coagulopathy and inflammation.25
In a recent military retrospective cohort study, Johnston and
colleagues26 reported that TXA was an independent risk fac-
tor for venous thromboembolism (odds ratio, 2.58; 95% CI,
1.20–5.56; p = 0.02), suggesting a reappraisal of its clinical
use in combat casualties. These potential adverse effects also
need to be considered for the prophylactic TXA use in pediat-
ric27 and adult25 elective and emergency surgeries.
On the fundamental question of survival benefit and opti-
mal timing of TXA administration, Gayet-Ageron and col-
leagues28 recently combined the CRASH-2 and WOMAN trial
data and performed a meta-analysis of individual participant-
level data involving 40,138 bleeding patients. They concluded
that the survival benefit of TXAwas greater than 70% (odds ra-
tio, 1.72; 95%CI, 1.42–2.10; p < 0.0001) within the first 3 hours
compared with later treatment and that the benefit decreased by
10% for every 15 minutes of treatment delay.28,29 The underly-
ing assumptions of this meta-analysis and the validity of com-
bining two large randomized controlled trials, each with their
own controversies, and using logistic regression models to gen-
erate clinically relevant data require further evaluation. Why the
meta-analysis did not include individual participant-level data
from other TXA studies, such as the MATTERs, or other mili-
tary studies is unfortunate. According to Gayet-Ageron and col-
leagues,28 any additional trials to increase patient numbers were
unlikely to have “a material effect on their conclusions.” How-
ever, we believe that broader inclusion criteria may help to
examine the type and magnitude of potential bias in their two-
trial meta-analysis. Notwithstanding these bona fide concerns,
it is surprising that in October 2017 the World Health Organiza-
tion revised their 2012 recommendations to include TXAwithin
3 hours for PPH.30
In conclusion, although we agree that TXA may have an
early survival benefit in patients who are severely bleeding with
or without shock,3,31 the results of the WOMAN trial are only a
beginning toward “saving one in three mothers who would oth-
erwise bleed to death after childbirth,” even if the drug is admin-
istered within 3 hours. We believe that the trial investigators and
social media have overstated the significance of the WOMAN
trial results, and combining the WOMAN and CRASH-2 data
in a meta-analysis may result in inherent bias. The need for a
consensus on what constitutes adequate statistical evidence for
a drug to be clinically useful, and do no harm, is at the heart of
our commentary. TXA should not be viewed as a one-size-fits-
all approach to treat blood loss in civilian- or combat-related
trauma or PPH, but rather we propose the incorporation of a
more precision-based set of guidelines for TXA administration
to reduce trauma-related and maternal mortality and morbidity.KEY POINTS
• p values do not address clinical significance.535
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Volume 84, Number 3• p values represent statistical significance based on the as-
sumption that the null hypothesis is true.
• p values need to be interpreted within their confidence band-
widths (or intervals) and sample size.
• When randomized trials or observational study sample sizes
are large, p values can be highly significant even if the effect
is small and clinically unimportant.
• Tranexamic acid should not be viewed as a one-size-fits-all
approach to treat blood loss.
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